Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 31.92
XON's Cash to Debt is ranked lower than
51% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. XON: 31.92 )
Ranked among companies with meaningful Cash to Debt only.
XON' s Cash to Debt Range Over the Past 10 Years
Min: 9.17  Med: 55.19 Max: N/A
Current: 31.92
Equity to Asset 0.60
XON's Equity to Asset is ranked lower than
60% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XON: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
XON' s Equity to Asset Range Over the Past 10 Years
Min: -2.12  Med: 0.69 Max: 0.8
Current: 0.6
-2.12
0.8
F-Score: 5
Z-Score: 4.00
M-Score: -3.39
WACC vs ROIC
12.85%
-25.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -55.59
XON's Operating margin (%) is ranked higher than
54% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. XON: -55.59 )
Ranked among companies with meaningful Operating margin (%) only.
XON' s Operating margin (%) Range Over the Past 10 Years
Min: -1028.67  Med: -244.2 Max: -55.59
Current: -55.59
-1028.67
-55.59
Net-margin (%) -96.65
XON's Net-margin (%) is ranked lower than
53% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. XON: -96.65 )
Ranked among companies with meaningful Net-margin (%) only.
XON' s Net-margin (%) Range Over the Past 10 Years
Min: -1064.27  Med: -164.06 Max: -48.67
Current: -96.65
-1064.27
-48.67
ROE (%) -29.08
XON's ROE (%) is ranked higher than
52% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. XON: -29.08 )
Ranked among companies with meaningful ROE (%) only.
XON' s ROE (%) Range Over the Past 10 Years
Min: -254.03  Med: -21.78 Max: -15.66
Current: -29.08
-254.03
-15.66
ROA (%) -19.38
XON's ROA (%) is ranked higher than
58% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. XON: -19.38 )
Ranked among companies with meaningful ROA (%) only.
XON' s ROA (%) Range Over the Past 10 Years
Min: -74.27  Med: -15.65 Max: -10.84
Current: -19.38
-74.27
-10.84
ROC (Joel Greenblatt) (%) -305.00
XON's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. XON: -305.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XON' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -460.38  Med: -243.33 Max: -160.11
Current: -305
-460.38
-160.11
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

XON Guru Trades in Q3 2015

First Eagle Investment 1,009,689 sh (+15.71%)
T Boone Pickens Sold Out
Daniel Loeb 1,500,000 sh (-44.44%)
» More
Q4 2015

XON Guru Trades in Q4 2015

Joel Greenblatt 57,418 sh (New)
Chase Coleman 1,675,000 sh (New)
First Eagle Investment 1,187,389 sh (+17.60%)
Daniel Loeb Sold Out
» More
Q1 2016

XON Guru Trades in Q1 2016

George Soros 57,100 sh (New)
Chase Coleman 2,093,199 sh (+24.97%)
First Eagle Investment 1,187,389 sh (unchged)
Joel Greenblatt 23,282 sh (-59.45%)
» More
Q2 2016

XON Guru Trades in Q2 2016

Murray Stahl 17,439 sh (New)
John Burbank 19,981 sh (New)
Joel Greenblatt 28,320 sh (+21.64%)
George Soros Sold Out
Chase Coleman Sold Out
First Eagle Investment 1,102,004 sh (-7.19%)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:JUNO, OTCPK:BTGGF, NAS:CBPO, NAS:ACAD, NAS:KITE, NAS:TECH, OTCPK:SOLTF, NAS:IONS, NAS:ICPT, NAS:RARE, NAS:EXEL, NAS:GLPG, NAS:ANAC, NAS:NKTR, NAS:LGND, NAS:TSRO, NAS:BLUE, NAS:ARIA, OTCPK:ABCZF, NAS:NVAX » details
Traded in other countries:I5X.Germany,
Intrexon Corp is a synthetic biology company that designs, builds and regulates gene programs using its proprietary and complementary technologies.

Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.

Ratios

vs
industry
vs
history
P/B 5.12
XON's P/B is ranked lower than
66% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. XON: 5.12 )
Ranked among companies with meaningful P/B only.
XON' s P/B Range Over the Past 10 Years
Min: 3.57  Med: 5.93 Max: 15.08
Current: 5.12
3.57
15.08
P/S 16.01
XON's P/S is ranked lower than
60% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. XON: 16.01 )
Ranked among companies with meaningful P/S only.
XON' s P/S Range Over the Past 10 Years
Min: 5.92  Med: 22.87 Max: 55.59
Current: 16.01
5.92
55.59
PFCF 86.64
XON's PFCF is ranked lower than
83% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. XON: 86.64 )
Ranked among companies with meaningful PFCF only.
XON' s PFCF Range Over the Past 10 Years
Min: 77.76  Med: 138.58 Max: 7130
Current: 86.64
77.76
7130
POCF 59.83
XON's POCF is ranked lower than
79% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. XON: 59.83 )
Ranked among companies with meaningful POCF only.
XON' s POCF Range Over the Past 10 Years
Min: 53.7  Med: 93.45 Max: 462.13
Current: 59.83
53.7
462.13
Current Ratio 3.62
XON's Current Ratio is ranked lower than
56% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. XON: 3.62 )
Ranked among companies with meaningful Current Ratio only.
XON' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.32 Max: 10.49
Current: 3.62
0.81
10.49
Quick Ratio 3.36
XON's Quick Ratio is ranked lower than
57% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. XON: 3.36 )
Ranked among companies with meaningful Quick Ratio only.
XON' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4 Max: 10.49
Current: 3.36
0.81
10.49
Days Inventory 143.24
XON's Days Inventory is ranked lower than
54% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. XON: 143.24 )
Ranked among companies with meaningful Days Inventory only.
XON' s Days Inventory Range Over the Past 10 Years
Min: 143.24  Med: 196.91 Max: 244.37
Current: 143.24
143.24
244.37
Days Sales Outstanding 51.70
XON's Days Sales Outstanding is ranked higher than
59% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. XON: 51.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.91  Med: 12.14 Max: 73.99
Current: 51.7
0.91
73.99
Days Payable 46.83
XON's Days Payable is ranked lower than
55% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. XON: 46.83 )
Ranked among companies with meaningful Days Payable only.
XON' s Days Payable Range Over the Past 10 Years
Min: 28.36  Med: 118.77 Max: 17536.59
Current: 46.83
28.36
17536.59

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.17
XON's Price/Tangible Book is ranked lower than
85% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. XON: 16.17 )
Ranked among companies with meaningful Price/Tangible Book only.
XON' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.9  Med: 11.96 Max: 27.65
Current: 16.17
6.9
27.65
Price/Median PS Value 0.77
XON's Price/Median PS Value is ranked higher than
64% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. XON: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
XON' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.92 Max: 2.21
Current: 0.77
0.32
2.21
Earnings Yield (Greenblatt) (%) -6.46
XON's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. XON: -6.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XON' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.31  Med: 0 Max: 0
Current: -6.46
-7.31
0

More Statistics

Revenue (TTM) (Mil) $190.8
EPS (TTM) $ -1.60
Beta1.51
Short Percentage of Float30.65%
52-Week Range $18.52 - 53.39
Shares Outstanding (Mil)118.33
» More Articles for NYSE:XON

Headlines

Articles On GuruFocus.com
The Emperor Has No Clothes Aug 17 2016 
CEO and Part Owner of JMP Group Invests in Company Jan 20 2016 
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections Aug 23 2016
INTREXON CORP Financials Aug 18 2016
Bullish bets on Intrexon, gold Aug 17 2016
How calls are playing for rally in Intrexon Aug 17 2016
ETF’s with exposure to Intrexon Corp. : August 15, 2016 Aug 15 2016
Obama Moves Money Around To Keep Zika Research Going Amid Lack Of Congressional Funds Allocation Aug 12 2016
Intrexon Corp. :XON-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
Arctic® Fuji apple one step closer to U.S. regulatory approval Aug 11 2016
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase Aug 10 2016
Intrexon CEO on Zika: We're working closely with FDA Aug 10 2016
Edited Transcript of XON earnings conference call or presentation 9-Aug-16 9:30pm GMT Aug 10 2016
Intrexon reports 2Q loss Aug 09 2016
Intrexon reports 2Q loss Aug 09 2016
Intrexon Announces Second Quarter and First Half 2016 Financial Results Aug 09 2016
INTREXON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Intrexon Announces Second Quarter and First Half 2016 Financial Results Aug 09 2016
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)